New Drug Targets Glioblastoma Cells with Specific Mutation
Author Information
Author(s): Dimitri G Trembath, Anita Lal, David J Kroll, Gregory J Riggins
Primary Institution: Johns Hopkins University School of Medicine
Hypothesis
Can small molecule inhibitors selectively target glioblastoma cells expressing the EGFRvIII mutation?
Conclusion
The compound NSC-154829 shows potential as an anti-glioblastoma drug by selectively inhibiting growth in cells with the EGFRvIII mutation.
Supporting Evidence
- NSC-154829 inhibited growth of glioblastoma cells with EGFRvIII while allowing normal cells to grow.
- Treatment with NSC-154829 increased apoptosis in EGFRvIII-expressing cells.
- IC50 values for EGFRvIII cells were significantly lower than for wild-type cells.
Takeaway
Scientists found a new drug that can kill brain cancer cells with a specific mutation while leaving normal cells alone.
Methodology
The study used isogenic cell lines to screen a library of small molecules for selective inhibitors of glioblastoma cells with the EGFRvIII mutation.
Limitations
The precise molecular mechanism of NSC-154829 is still undefined, and the study is preliminary.
Statistical Information
P-Value
p<0.0001
Confidence Interval
(0.27–0.84)
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website